Ablynx (OTCMKTS:ABLYF) and Champions Oncology (NASDAQ:CSBR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Ablynx and Champions Oncology, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ablynx 0 0 0 0 N/A
Champions Oncology 0 0 4 0 3.00

Champions Oncology has a consensus price target of $13.00, suggesting a potential upside of 28.21%.

Earnings & Valuation

This table compares Ablynx and Champions Oncology’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ablynx $62.73 million 0.00 -$122.67 million N/A N/A
Champions Oncology $20.24 million 5.75 -$1.47 million ($0.14) -72.43

Champions Oncology has lower revenue, but higher earnings than Ablynx.

Volatility and Risk

Ablynx has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

Profitability

This table compares Ablynx and Champions Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ablynx N/A N/A N/A
Champions Oncology 0.05% 1.44% 0.13%

Insider & Institutional Ownership

52.6% of Champions Oncology shares are owned by institutional investors. 44.3% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Champions Oncology beats Ablynx on 7 of the 9 factors compared between the two stocks.

About Ablynx

Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

About Champions Oncology

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The company also offers POS products, including personalized tumor boards that are designed to provide access to oncologists with expertise in particular tumor types; and provides access to gene sequencing that analyzes the genetic makeup of patient's tumor for the purpose of identifying potentially useful drugs. In addition, it offers Translational Oncology Solutions, including a preclinical Tumorgraft platform to pharmaceutical and biotechnology companies. Champions Oncology, Inc. markets its products through Internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011 to reflect its new focus on developing technologies to personalize the development and use of oncology drugs. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings for Ablynx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx and related companies with MarketBeat.com's FREE daily email newsletter.